CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Cytokine conjugation to enhance T cell therapy.
Cytokine conjugation to enhance T cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
过继T细胞转移(ACT)疗法存在多项局限,例如对实体瘤控制不佳。ACT联合细胞因子治疗虽然可能提高疗效,但也会引起显著副作用。本文介绍一种纳米技术方法:在制造过程中利用非天然糖纳米颗粒对T细胞进行代谢标记,从而将抗肿瘤细胞因子直接偶联到T细胞表面,以提高ACT疗效。该方法可使原本具有毒性的细胞因子在局部高浓度发挥作用。它能够增加T细胞向实体瘤浸润,促使宿主免疫系统产生I型免疫应答,促进抗原扩展,并改善对侵袭性实体瘤的控制;此外,即使CAR-T 细胞剂量不足以单独治愈血液癌症,该方法仍可促成肿瘤完全消退。总体而言,这种方法有效且易于整合至现有ACT生产流程,有望在多种治疗情境中提高疗效。
Adoptive T cell transfer (ACT) therapies suffer from a number of limitations (e. g. , poor control of solid tumors), and while combining ACT with cytokine therapy can enhance effectiveness, this also results in significant side effects.
Here, we describe a nanotechnology approach to improve the efficacy of ACT therapies by metabolically labeling T cells with unnatural sugar nanoparticles, allowing direct conjugation of antitumor cytokines onto the T cell surface during the manufacturing process. This allows local, concentrated activity of otherwise toxic cytokines.
This approach increases T cell infiltration into solid tumors, activates the host immune system toward a Type 1 response, encourages antigen spreading, and improves control of aggressive solid tumors and achieves complete blood cancer regression with otherwise noncurative doses of CAR-T cells.
Overall, this method provides an effective and easily integrated approach to the current ACT manufacturing process to increase efficacy in various settings.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。